Proteomic Learning of Gamma-Aminobutyric Acid (GABA) Receptor-Mediated Anesthesia

• URL: http://arxiv.org/abs/2501.02824v1
• Date: Mon, 06 Jan 2025 07:55:39 GMT
• Title: Proteomic Learning of Gamma-Aminobutyric Acid (GABA) Receptor-Mediated Anesthesia
• Authors: Jian Jiang, Long Chen, Yueying Zhu, Yazhou Shi, Huahai Qiu, Bengong Zhang, Tianshou Zhou, Guo-Wei Wei,
• Abstract summary: We introduce a proteomic learning of GABA receptor-mediated anesthesia based on 24 GABA receptor subtypes.<n>We curated a dataset comprising 136 targets from a pool of 980 targets within the PPI networks.<n>We evaluated the side effects and repurposing potential of over 180,000 drug candidates targeting the GABRA5 receptor.
• Score: 6.428865757072811
• License: http://arxiv.org/licenses/nonexclusive-distrib/1.0/
• Abstract: Anesthetics are crucial in surgical procedures and therapeutic interventions, but they come with side effects and varying levels of effectiveness, calling for novel anesthetic agents that offer more precise and controllable effects. Targeting Gamma-aminobutyric acid (GABA) receptors, the primary inhibitory receptors in the central nervous system, could enhance their inhibitory action, potentially reducing side effects while improving the potency of anesthetics. In this study, we introduce a proteomic learning of GABA receptor-mediated anesthesia based on 24 GABA receptor subtypes by considering over 4000 proteins in protein-protein interaction (PPI) networks and over 1.5 millions known binding compounds. We develop a corresponding drug-target interaction network to identify potential lead compounds for novel anesthetic design. To ensure robust proteomic learning predictions, we curated a dataset comprising 136 targets from a pool of 980 targets within the PPI networks. We employed three machine learning algorithms, integrating advanced natural language processing (NLP) models such as pretrained transformer and autoencoder embeddings. Through a comprehensive screening process, we evaluated the side effects and repurposing potential of over 180,000 drug candidates targeting the GABRA5 receptor. Additionally, we assessed the ADMET (absorption, distribution, metabolism, excretion, and toxicity) properties of these candidates to identify those with near-optimal characteristics. This approach also involved optimizing the structures of existing anesthetics. Our work presents an innovative strategy for the development of new anesthetic drugs, optimization of anesthetic use, and deeper understanding of potential anesthesia-related side effects.

Related papers

• Fitness aligned structural modeling enables scalable virtual screening with AuroBind [56.720030595081845]
  We present AuroBind, a scalable virtual screening framework that fine-tunes a custom atomic-level structural model on million-scale chemogenomic data.<n>AuroBind integrates direct preference optimization, self-distillation from high-confidence complexes, and a teacher-student acceleration strategy.<n>In a prospective screen across ten disease-relevant targets, AuroBind achieved experimental hit rates of 7-69%, with top compounds reaching sub-nanomolar to picomolar potency.
  arXiv  Detail & Related papers  (2025-08-04T07:34:48Z)
• A Computational Approach to Epilepsy Treatment: An AI-optimized Global Natural Product Prescription System [0.5439020425819]
  Epilepsy is a prevalent neurological disease with millions of patients worldwide.<n>Many have turned to alternative medicine due to limited efficacy and side effects of conventional antiepileptic drugs.<n>We developed a computational approach to optimize herbal epilepsy treatment through AI-driven analysis of global natural products.
  arXiv  Detail & Related papers  (2025-05-10T08:14:20Z)
• E2CB2former: Effecitve and Explainable Transformer for CB2 Receptor Ligand Activity Prediction [11.078168240910147]
  CB2former is a framework that combines a Graph Convolutional Network with a Transformer architecture to predict CB2 receptor ligand activity. We benchmark CB2former against diverse baseline models and demonstrate its superior performance with an R squared of 0.685, an RMSE of 0.675, and an AUC of 0.940. Our results showcase the transformative potential of advanced AI approaches exemplified by CB2former in delivering both accurate predictions and actionable molecular insights.
  arXiv  Detail & Related papers  (2025-02-15T05:05:49Z)
• DrugImproverGPT: A Large Language Model for Drug Optimization with Fine-Tuning via Structured Policy Optimization [53.27954325490941]
  Finetuning a Large Language Model (LLM) is crucial for generating results towards specific objectives. This research introduces a novel reinforcement learning algorithm to finetune a drug optimization LLM-based generative model.
  arXiv  Detail & Related papers  (2025-02-11T04:00:21Z)
• To Explore the Potential Inhibitors against Multitarget Proteins of COVID 19 using In Silico Study [0.0]
  The global pandemic due to emergence of COVID 19 has created the unrivaled public health crisis. We used the combination of molecular docking and machine learning regression approaches to explore the potential inhibitors for the treatment of COVID 19. We proposed five novel promising inhibitors with their respective Zinc IDs ZINC (3873365, 85432544, 8214470, 85536956, and 261494640) within the range of -19.7 kcal/mol to -12.6 kcal/mol.
  arXiv  Detail & Related papers  (2024-09-24T22:19:56Z)
• Fragment-Masked Diffusion for Molecular Optimization [71.13210858056527]
  We propose a fragment-masked molecular optimization method based on phenotypic drug discovery (PDD)<n>PDD-based molecular optimization can reduce potential safety risks while optimizing phenotypic activity, thereby increasing the likelihood of clinical success.<n>The overall experiments demonstrate that the in-silico optimization success rate reaches 95.4%, with an average efficacy increase of 7.5%.
  arXiv  Detail & Related papers  (2024-08-17T06:00:58Z)
• A Cross-Field Fusion Strategy for Drug-Target Interaction Prediction [85.2792480737546]
  Existing methods fail to utilize global protein information during DTI prediction. Cross-field information fusion strategy is employed to acquire local and global protein information. Siamese drug-target interaction SiamDTI prediction method achieves higher accuracy levels than other state-of-the-art (SOTA) methods on novel drugs and targets.
  arXiv  Detail & Related papers  (2024-05-23T13:25:20Z)
• CardioGenAI: A Machine Learning-Based Framework for Re-Engineering Drugs for Reduced hERG Liability [0.0]
  We present CardioGenAI, a machine learning-based framework for re-engineering both developmental and commercially available drugs for reduced hERG activity. We applied the complete framework to pimozide, an FDA-approved antipsychotic agent, and generated 100 refined candidates. We envision that this method can effectively be applied to developmental compounds exhibiting hERG liabilities to provide a means of rescuing drug development programs that have stalled due to hERG-related safety concerns.
  arXiv  Detail & Related papers  (2024-03-12T13:12:24Z)
• Emerging Drug Interaction Prediction Enabled by Flow-based Graph Neural Network with Biomedical Network [69.16939798838159]
  We propose EmerGNN, a graph neural network (GNN) that can effectively predict interactions for emerging drugs. EmerGNN learns pairwise representations of drugs by extracting the paths between drug pairs, propagating information from one drug to the other, and incorporating the relevant biomedical concepts on the paths. Overall, EmerGNN has higher accuracy than existing approaches in predicting interactions for emerging drugs and can identify the most relevant information on the biomedical network.
  arXiv  Detail & Related papers  (2023-11-15T06:34:00Z)
• Machine Learning Study of the Extended Drug-target Interaction Network informed by Pain Related Voltage-Gated Sodium Channels [8.746692914034016]
  Pain is a significant global health issue, and the current treatment options for pain management have limitations in terms of effectiveness, side effects, and potential for addiction. In this study, we construct protein-protein interaction (PPI) networks based on pain-related sodium channels. We employ three distinct machine learning algorithms combined with advanced natural language processing (NLP)-based embeddings, specifically pre-trained transformer and autoencoder representations.
  arXiv  Detail & Related papers  (2023-07-11T20:40:31Z)
• Drug Repurposing Targeting COVID-19 3CL Protease using Molecular Docking and Machine Learning Regression Approach [0.15346678870160887]
  The COVID-19 pandemic has initiated a global health emergency, with an exigent need for effective cure. We screened the 5903 approved drugs for their inhibition by targeting the main protease 3CL of SARS-CoV-2. We employed several machine learning regression approaches for QSAR modeling to find out some potential drugs with high binding affinities.
  arXiv  Detail & Related papers  (2023-05-25T05:34:39Z)
• Tailoring Molecules for Protein Pockets: a Transformer-based Generative Solution for Structured-based Drug Design [133.1268990638971]
  De novo drug design based on the structure of a target protein can provide novel drug candidates. We present a generative solution named TamGent that can directly generate candidate drugs from scratch for a given target.
  arXiv  Detail & Related papers  (2022-08-30T09:32:39Z)
• Improved Drug-target Interaction Prediction with Intermolecular Graph Transformer [98.8319016075089]
  We propose a novel approach to model intermolecular information with a three-way Transformer-based architecture. Intermolecular Graph Transformer (IGT) outperforms state-of-the-art approaches by 9.1% and 20.5% over the second best for binding activity and binding pose prediction respectively. IGT exhibits promising drug screening ability against SARS-CoV-2 by identifying 83.1% active drugs that have been validated by wet-lab experiments with near-native predicted binding poses.
  arXiv  Detail & Related papers  (2021-10-14T13:28:02Z)
• An Interpretable Framework for Drug-Target Interaction with Gated Cross Attention [4.746451824931381]
  In this study, we propose a novel interpretable framework that can provide reasonable cues for the interaction sites. We elaborately design a gated cross-attention mechanism that crossly attends drug and target features by constructing explicit interactions between these features. The experimental results show the efficacy of the proposed method in two DTI datasets.
  arXiv  Detail & Related papers  (2021-09-17T05:53:40Z)
• SafeDrug: Dual Molecular Graph Encoders for Safe Drug Recommendations [59.590084937600764]
  We propose a DDI-controllable drug recommendation model named SafeDrug to leverage drugs' molecule structures and model DDIs explicitly. On a benchmark dataset, our SafeDrug is relatively shown to reduce DDI by 19.43% and improves 2.88% on Jaccard similarity between recommended and actually prescribed drug combinations over previous approaches.
  arXiv  Detail & Related papers  (2021-05-05T00:20:48Z)
• Reinforcement learning and Bayesian data assimilation for model-informed precision dosing in oncology [0.0]
  Current strategies comprise model-informed dosing tables or are based on maximum a-posteriori estimates. We propose three novel approaches for MIPD employing Bayesian data assimilation and/or reinforcement learning to control neutropenia. These approaches have the potential to substantially reduce the incidence of life-threatening grade 4 and subtherapeutic grade 0 neutropenia.
  arXiv  Detail & Related papers  (2020-06-01T16:38:27Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.